# HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

> **NCT06328387** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 120 (estimated)

## Conditions studied

- Advanced Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** Sacituzumab Govitecan
- **DRUG:** Trastuzumab Deruxtecan

## Key facts

- **NCT ID:** NCT06328387
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-29
- **Primary completion:** 2026-02-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06328387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06328387, "HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT06328387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*